{
    "clinical_study": {
        "@rank": "52063", 
        "arm_group": [
            {
                "arm_group_label": "Initiation cohort", 
                "description": "Receive their first prescription for ICS therapy as one of the study drugs"
            }, 
            {
                "arm_group_label": "Step-up cohort", 
                "description": "Receive a prescription for one of the study drugs at a dose \u226550% that of their prescribed ICS dose during baseline."
            }, 
            {
                "arm_group_label": "Switch cohort", 
                "description": "switch from BUD DPI (other) to BUD EH or continue on BUD DPI (other) with no change in ICS dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to compare the clinical effectiveness and cost-effectiveness of the\n      Easyhaler\u00ae (EH) device and other DPI devices commonly used in the UK in a UK primary care\n      asthma population of patients aged 6 to 80 years."
        }, 
        "brief_title": "Real Life Effectiveness of Easyhaler (Orion)", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "A recent observational study by Price et al  carried out using the UK's General Practice\n      Research Database (CPRD) to compare asthma-related outcomes for different inhaled\n      corticosteroid (ICS) inhaler devices, using Easyhaler and dry powder inhalers (DPIs)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must also meet the following inclusion criteria:\n\n          -  (1) Aged: 6-80 years - stratified 6-11 years; 12-60 years; \u226561 years to allow\n             paediatrics and adolescent / adult sub analyses; and to allow for the exclusion of\n             elderly (aged 61+) smokers and ex-smokers if required.\n\n          -  (2) On-going asthma therapy: \u22652 prescriptions for asthma during the outcome period\n             (i.e. \u22651 prescription (for any asthma therapy) in addition to the prescription for\n             ICS at IPD (initiation / step-up/ switch).\n\n          -  (3) Evidence of active asthma:\n\n               1. Initiation -  a diagnostic code for asthma\n\n               2. Step-up / Switch - \u22652 prescriptions for asthma (at least one of which is for\n                  ICS) at different points in time during the baseline year PLUS a diagnostic code\n                  for asthma.\n\n          -  (4) Have at least one year of up-to-standard (UTS) baseline data and at least one\n             year of UTS outcome data (following the IPD).\n\n        Exclusion Criteria:\n\n          -  Patients will be excluded from the analysis if they have:\n\n          -  (1) Had a COPD read code at any time; and/or\n\n          -  (2) Had any chronic respiratory disease, except asthma, at any time; and/or\n\n          -  (3) Patients on maintenance oral steroids during baseline year; and/or\n\n          -  (4) Multiple ICS prescriptions at IPD."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "6 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "This will be a retrospective, observational study consisting of a one-year baseline period\n        immediately prior to an index prescription date (IPD), and a one-year outcome period\n        immediately following the index date.\n\n        At the IPD, patients either:\n\n          -  Initiation cohort: receive their first prescription for ICS therapy as one of the\n             study drugs\n\n          -  Step-up cohort: receive a prescription for one of the study drugs at a dose \u226550% that\n             of their prescribed ICS dose during baseline.\n\n          -  Switch cohort: switch from BUD DPI (other) to BUD EH or continue on BUD DPI (other)\n             with no change in ICS dose"
            }
        }, 
        "enrollment": {
            "#text": "24003", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02048930", 
            "org_study_id": "R02411"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Initiation cohort", 
                    "Step-up cohort", 
                    "Switch cohort"
                ], 
                "intervention_name": "Budesonide Easyhaler", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Initiation cohort", 
                    "Step-up cohort", 
                    "Switch cohort"
                ], 
                "intervention_name": "Budesonide dry powder inhaler", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Budesonide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "GPRD", 
            "effectiveness", 
            "cost-effectiveness", 
            "Easyhaler", 
            "Primary care", 
            "DPI"
        ], 
        "lastchanged_date": "January 28, 2014", 
        "link": [
            {
                "url": "http://www.optimumpatientcare.org/Html_Docs/OPCRD.html"
            }, 
            {
                "url": "http://www.cprd.com/intro.asp"
            }
        ], 
        "number_of_groups": "3", 
        "official_title": "Effectiveness and Cost-effectiveness Evaluation of Easyhaler Versus Other Devices in a Real World Primary Care Population", 
        "overall_official": {
            "affiliation": "Research in real life", 
            "last_name": "David Price", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The Composite proxy for asthma control (excluding SABA usage) during the one-year outcome period, which is defined as:\nControlled: the absence of the following during the one-year outcome period:\n(i) Asthma-related :\nHospital attendance or admission\nA&E attendance, OR\nOut of hours attendance, OR\nOut-patient department attendance\n(ii) GP consultations for lower respiratory tract infection\n(iii) Prescriptions for acute courses of oral steroids  ;\nUncontrolled: all others.", 
                "measure": "asthma control (excluding SABA usage)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Total number of asthma exacerbations (ATS Definition) defined as an occurrence of:\n(i) Asthma-related:\nHospital attendance / admissions OR\nA&E attendance\n(ii) Use of acute oral steroids.", 
                "measure": "exacerbations (ATS definition)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Total number of asthma exacerbations (Clinical Definition) defined as an occurrence of:\n(i) Asthma-related:\nHospital attendance / admissions, OR\nA&E attendance, OR\n(ii) GP consultations for lower respiratory related tract infections\n(iii) Use of acute oral steroids.", 
                "measure": "exacerbations (Clinical definition)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "The Composite proxy for asthma control (including SABA usage) during the one-year outcome period, which is defined as:\nControlled: the absence of the following during the one-year outcome period:\n(iv) Asthma-related :\nHospital attendance or admission\nA&E attendance, OR\nOut of hours attendance, OR\nOut-patient department attendance\n(v) GP consultations for lower respiratory tract infection\n(vi) Prescriptions for acute courses of oral steroids  ;\nPlus:\n(vii) Average prescribed daily dose \u2264200mg of Salbutamol / \u2264500mg of terbutaline.\nUncontrolled: all others.", 
                "measure": "asthma control (including SABA usage)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02048930"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Treatment Success (Definition 1) defined as:\nSuccessful:  the absence of the following during the one-year outcome period\n(i) Asthma-related:\nHospital attendance or admission\nA&E attendance, OR\nOut of hours attendance, OR\nOut-patient department attendance\n(ii) GP consultations for lower respiratory tract infection\n(iii) Prescriptions for acute courses of oral steroids\n(iv) Any additional or change in therapy:\nIncreased dose of ICS (\u226550% increase), and/or\nChange in ICS and/or\nChange in delivery device, and/or\nUse of additional therapy as defined by: theophylline and leukotreine receptor antagonists (LTRAs).\nUnsuccessful: all others.", 
                "measure": "treatment success definition 1", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "(average daily dose during outcome year)", 
                "measure": "SABA dosages", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "categorised as: <50%, 50-<70%, 70-<100%, \u2265100%.", 
                "measure": "adherence to ICS therapy", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "The Medication Possession Ratio (MPR) for ICS is defined using the following formula.\nMedication Possession Ratio =  (no. of days supply of ICS/365)x 100% The numerator is truncated at 365 if greater than 365. The MPR is a measure of adherence to therapy and a cut-off of 80% has previously been used   in categorising asthma patients as adherent or non-adherent; the MPR has therefore been categorised as a dichotomous variable: < 80% and \u2265 80% for this analysis.", 
                "measure": "Medication Possession Ratio (MPR)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Treatment Success (Definition 2) defined as:\nSuccessful:  the absence of the following during the one-year outcome period\n(i) Asthma-related:\nHospital attendance or admission\nA&E attendance, OR\nOut of hours attendance, OR\nOut-patient department attendance\n(ii) GP consultations for lower respiratory tract infection\n(iii) Prescriptions for acute courses of oral steroids7\n(iv) Any additional or change in therapy:\nIncreased dose of ICS (\u226550% increase), and/or\nUse of additional therapy as defined by: theophylline and leukotreine receptor antagonists (LTRAs).\nUnsuccessful: all others.", 
                "measure": "Treatment success (definition 2)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Research in Real-Life Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Orion Corporation, Orion Pharma", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Research in Real-Life Ltd", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}